Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin to focus on...

    Lupin to focus on launch of biosimilar, inhalation product in US this fiscal

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-15T09:45:42+05:30  |  Updated On 17 Aug 2021 10:56 AM IST

    Coupling this with the building of Solosec brand in the US, NaMuscla in Europe and Bipresso in Japan will help Lupin drive sustainable growth, they added.


    New Delhi: Drug maker Lupin aims to launch its first biosimilar product and commercialise its first inhalation product in the US in the current fiscal. Addressing shareholders in the company's Annual Report for 2018-19, Lupin Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta said the new launches across the globe would help it achieve sustainable growth.


    Read Also: Lupin unveils generic Imatinib Mesylate tablets to treat types of cancer


    "Looking ahead, FY2020 is an exciting year for Lupin as we plan to bring our first biosimilar to market, commercialise our first inhalation product in the US, continue the growth momentum in our US generics business and launch our injectables portfolio," they said in a joint letter to the shareholders.


    Coupling this with the building of Solosec brand in the US, NaMuscla in Europe and Bipresso in Japan will help the company drive sustainable growth, they added.


    "Creating a growth business while making a difference, has been our ambition. We are committed to building a promising future. We will deliver this by executing on our well-defined strategic priorities, investing in capabilities and manufacturing excellence to support operations that meet the highest standards," the company's leadership said.


    The firm's first biosimilar Etanercept is approved for launch in Japan, while the European approval is awaited, the report said.


    Lupin said it launched 22 new products in the US market last fiscal.


    "With over 157 abbreviated new drug applications (ANDAs) currently pending approval with the USFDA, we have a rich pipeline addressing a total market size of over USD 52 billion," the letter said.


    Read Also: Lupin gets USFDA nod for generic versions of Sensipar tablets, Omidria intraocular solution


    Lupin added that while there were many successes throughout the course of the last financial year, the company also faced many challenges on the compliance front.


    "We had our share of challenges, particularly, on the compliance front. We have made significant progress on our remediation and enhancement plan and are committed to sustainable compliance throughout all our sites. As an organisation this is one of our biggest priorities," the letter said.


    The Mumbai-based company's various manufacturing plants have come under the US Food and Drug Adminstration's (USFDA) scanner for various compliance issues.

    biosimilar productBipressoEtanerceptfiscal 2019FY2020geographiesinhalation productLaunchLupinNaMusclanew productNilesh Guptapharmapharma companypharma newspharma news indiaSolosec brandUS Food and Drug AdminstrationUSFDAVinita Gupta
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok